Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Mucin Glycans: A Target for Cancer Therapy

Version 1 : Received: 16 September 2023 / Approved: 18 September 2023 / Online: 18 September 2023 (09:39:45 CEST)

A peer-reviewed article of this Preprint also exists.

Sun, L.; Zhang, Y.; Li, W.; Zhang, J.; Zhang, Y. Mucin Glycans: A Target for Cancer Therapy. Molecules 2023, 28, 7033. Sun, L.; Zhang, Y.; Li, W.; Zhang, J.; Zhang, Y. Mucin Glycans: A Target for Cancer Therapy. Molecules 2023, 28, 7033.

Abstract

Mucin glycans are important component of the mucus barrier and vital defence against physical and chemical damage as well as pathogens. Abnormal expression of mucin glycans can lead to disease, especially cancer. Here, we first summarize the main types of glycosylation on mucins and the mechanisms by which abnormal mucin glycans occur. We next describe the role of ab-normal mucin glycans in cancer. Finally, we describe MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example.

Keywords

mucin; glycosylation; cancer; MUC1; targeted therapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.